Amgen's Blincyto Is First Cancer Drug To Get Medicare Add-On Payments
CMS agrees to provide new technology add-on payments for Amgen’s cancer drug for acute lymphoblastic leukemia after the company documents Blincyto’s uniqueness and its advantages over existing treatments.